| Endocrine side effects induced by immune checkpoint inhibitors SM Corsello, A Barnabei, P Marchetti, L De Vecchis, R Salvatori, F Torino The Journal of Clinical Endocrinology & Metabolism 98 (4), 1361-1375, 2013 | 465 | 2013 |
| Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study M Muscaritoli, S Lucia, A Farcomeni, V Lorusso, V Saracino, C Barone, ... Oncotarget 8 (45), 79884, 2017 | 392 | 2017 |
| A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 335 | 2019 |
| Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma E Simeone, G Gentilcore, D Giannarelli, AM Grimaldi, C Caracò, ... Cancer immunology, immunotherapy 63, 675-683, 2014 | 274 | 2014 |
| Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents G Minniti, R Muni, G Lanzetta, P Marchetti, RM Enrici Anticancer research 29 (12), 5171-5184, 2009 | 255 | 2009 |
| Use of strong opioids in advanced cancer pain: a randomized trial F Marinangeli, A Ciccozzi, M Leonardis, L Aloisio, A Mazzei, A Paladini, ... Journal of pain and symptom management 27 (5), 409-416, 2004 | 248 | 2004 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 226 | 2018 |
| Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients PF Ferrucci, S Gandini, A Battaglia, S Alfieri, AM Di Giacomo, ... British journal of cancer 112 (12), 1904-1910, 2015 | 225 | 2015 |
| Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort PA Ascierto, E Simeone, VC Sileni, J Pigozzo, M Maio, M Altomonte, ... Journal of translational medicine 12, 1-7, 2014 | 185 | 2014 |
| Immunotherapy in the treatment of metastatic melanoma: current knowledge and future directions M Ralli, A Botticelli, IC Visconti, D Angeletti, M Fiore, P Marchetti, ... Journal of immunology research 2020, 2020 | 177 | 2020 |
| Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab U De Giorgi, G Procopio, D Giannarelli, R Sabbatini, A Bearz, S Buti, ... Clinical Cancer Research 25 (13), 3839-3846, 2019 | 176 | 2019 |
| Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell … T Di Pucchio, L Pilla, I Capone, M Ferrantini, E Montefiore, F Urbani, ... Cancer research 66 (9), 4943-4951, 2006 | 166 | 2006 |
| Physical exercise and quality of life in breast cancer survivors M Valenti, G Porzio, F Aielli, L Verna, K Cannita, R Manno, F Masedu, ... International journal of medical sciences 5 (1), 24, 2008 | 161 | 2008 |
| Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ... Journal for immunotherapy of cancer 8 (2), 2020 | 160 | 2020 |
| Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma M Del Vecchio, L Di Guardo, PA Ascierto, AM Grimaldi, VC Sileni, ... European Journal of Cancer 50 (1), 121-127, 2014 | 157 | 2014 |
| KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ... Annals of Oncology 31 (12), 1746-1754, 2020 | 156 | 2020 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 153 | 2019 |
| Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma M Maio, R Danielli, V Chiarion-Sileni, J Pigozzo, G Parmiani, R Ridolfi, ... Annals of Oncology 24 (11), 2911-2915, 2013 | 153 | 2013 |
| Triple positive breast cancer: a distinct subtype? P Vici, L Pizzuti, C Natoli, T Gamucci, L Di Lauro, M Barba, D Sergi, ... Cancer treatment reviews 41 (2), 69-76, 2015 | 147 | 2015 |
| Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment A Botticelli, P Vernocchi, F Marini, A Quagliariello, B Cerbelli, S Reddel, ... Journal of translational medicine 18, 1-10, 2020 | 138 | 2020 |
